Adult medulloblastoma: Multiagent chemotherapy with cisplatinum and etoposide: A single institutional experience

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In 1991, a prospective phase II trial was initiated to evaluate the efficacy of treatment for adults with medulloblastoma (MB). After surgery, patients were staged with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology. All patients received three cycles of upfront cisplatinum (cisplatinum) and etoposide (VP16) chemotherapy followed by craniospinal radiation therapy. The current article reports on the long-term results from that trial. After a median follow-up of 14.9 years, among a total of 28 adults with MB, the overall progression-free survival and overall survival (OS) rates at 5 years were 57.6 and 80%, respectively. The median OS for the whole group of patients was 11.3 years. The observed toxicity was mainly hematological, with leukopenia and thrombocytopenia (16% of grades 3 and 4). In summary, in our small series of patients, the role of combination administration of CDDP ? VP16 started before the initiation of radiotherapy in reducing recurrences, particularly distant recurrences, remains unclear. To know whether adding chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.

Original languageEnglish
Pages (from-to)595-600
Number of pages6
JournalJournal of Neuro-Oncology
Volume106
Issue number3
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Medulloblastoma
Etoposide
Drug Therapy
Recurrence
Radiotherapy
Survival
Leukopenia
Thrombocytopenia
Disease-Free Survival
Cell Biology
Cerebrospinal Fluid
Survival Rate
Randomized Controlled Trials
Radiation
Brain
Therapeutics

Keywords

  • Adult patients
  • Chemotherapy
  • Cisplatinum
  • Etoposide
  • Medulloblastoma

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

@article{2ed1ede468254bfa99477dec4009cad3,
title = "Adult medulloblastoma: Multiagent chemotherapy with cisplatinum and etoposide: A single institutional experience",
abstract = "In 1991, a prospective phase II trial was initiated to evaluate the efficacy of treatment for adults with medulloblastoma (MB). After surgery, patients were staged with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology. All patients received three cycles of upfront cisplatinum (cisplatinum) and etoposide (VP16) chemotherapy followed by craniospinal radiation therapy. The current article reports on the long-term results from that trial. After a median follow-up of 14.9 years, among a total of 28 adults with MB, the overall progression-free survival and overall survival (OS) rates at 5 years were 57.6 and 80{\%}, respectively. The median OS for the whole group of patients was 11.3 years. The observed toxicity was mainly hematological, with leukopenia and thrombocytopenia (16{\%} of grades 3 and 4). In summary, in our small series of patients, the role of combination administration of CDDP ? VP16 started before the initiation of radiotherapy in reducing recurrences, particularly distant recurrences, remains unclear. To know whether adding chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.",
keywords = "Adult patients, Chemotherapy, Cisplatinum, Etoposide, Medulloblastoma",
author = "A. Silvani and P. Gaviani and E. Lamperti and A. Botturi and F. DiMeco and A. Franzini and P. Ferroli and L. Fariselli and I. Milanesi and A. Erbetta and B. Pollo and A. Salmaggi",
year = "2012",
month = "2",
doi = "10.1007/s11060-011-0696-0",
language = "English",
volume = "106",
pages = "595--600",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Adult medulloblastoma

T2 - Multiagent chemotherapy with cisplatinum and etoposide: A single institutional experience

AU - Silvani, A.

AU - Gaviani, P.

AU - Lamperti, E.

AU - Botturi, A.

AU - DiMeco, F.

AU - Franzini, A.

AU - Ferroli, P.

AU - Fariselli, L.

AU - Milanesi, I.

AU - Erbetta, A.

AU - Pollo, B.

AU - Salmaggi, A.

PY - 2012/2

Y1 - 2012/2

N2 - In 1991, a prospective phase II trial was initiated to evaluate the efficacy of treatment for adults with medulloblastoma (MB). After surgery, patients were staged with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology. All patients received three cycles of upfront cisplatinum (cisplatinum) and etoposide (VP16) chemotherapy followed by craniospinal radiation therapy. The current article reports on the long-term results from that trial. After a median follow-up of 14.9 years, among a total of 28 adults with MB, the overall progression-free survival and overall survival (OS) rates at 5 years were 57.6 and 80%, respectively. The median OS for the whole group of patients was 11.3 years. The observed toxicity was mainly hematological, with leukopenia and thrombocytopenia (16% of grades 3 and 4). In summary, in our small series of patients, the role of combination administration of CDDP ? VP16 started before the initiation of radiotherapy in reducing recurrences, particularly distant recurrences, remains unclear. To know whether adding chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.

AB - In 1991, a prospective phase II trial was initiated to evaluate the efficacy of treatment for adults with medulloblastoma (MB). After surgery, patients were staged with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology. All patients received three cycles of upfront cisplatinum (cisplatinum) and etoposide (VP16) chemotherapy followed by craniospinal radiation therapy. The current article reports on the long-term results from that trial. After a median follow-up of 14.9 years, among a total of 28 adults with MB, the overall progression-free survival and overall survival (OS) rates at 5 years were 57.6 and 80%, respectively. The median OS for the whole group of patients was 11.3 years. The observed toxicity was mainly hematological, with leukopenia and thrombocytopenia (16% of grades 3 and 4). In summary, in our small series of patients, the role of combination administration of CDDP ? VP16 started before the initiation of radiotherapy in reducing recurrences, particularly distant recurrences, remains unclear. To know whether adding chemotherapy to craniospinal radiation in adult therapy increases relapse-free and overall survival, we must await the results of a larger randomized controlled clinical trial.

KW - Adult patients

KW - Chemotherapy

KW - Cisplatinum

KW - Etoposide

KW - Medulloblastoma

UR - http://www.scopus.com/inward/record.url?scp=84857049683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857049683&partnerID=8YFLogxK

U2 - 10.1007/s11060-011-0696-0

DO - 10.1007/s11060-011-0696-0

M3 - Article

C2 - 21874383

AN - SCOPUS:84857049683

VL - 106

SP - 595

EP - 600

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -